Tag: Multiple Myeloma
Diabetes More Prevalent in Black Patients With Multiple Myeloma
Diabetes linked to reduced overall survival, especially in Whites; in mouse model, progression of MM xenografts faster in mice with diabetes
IVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA Therapy
Reduction in grade 3 to 5 infections seen among patients with multiple myeloma treated with BCMA-targeted bispecific antibodies
FDA Provides Accelerated Approval of Talvey for Multiple Myeloma
Talvey, a bispecific therapy, indicated for the treatment of patients with relapsed, refractory, heavily pretreated multiple myeloma
Younger Patients With Multiple Myeloma Can Achieve Durable Survival
Depth of response following autologous stem cell transplant remains a key predictor of survival
Multiple Myeloma Symptoms Are Generally Nonspecific
Vertebral fractures, underrecognized as pathological, were main cause of irreversible organ damage
ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
Single cilta-cel infusion results in lower risk of disease progression or death compared with standard care
Eligibility Criteria May Influence Disparity in Multiple Myeloma Trial Enrollment
Blacks and other race subgroups have higher multiple myeloma trial ineligibility rates compared with Whites
Prognosis of Multiple Myeloma Has Improved Since 2000
However, multiple myeloma patients still have elevated likelihood of dying from nonmyeloma malignancies, CVDs
Minimal Residual Disease Negativity Predicts Time to Next Treatment in Multiple Myeloma
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics
Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma
Ide-cel significantly improves progression-free survival and response compared with standard regimens
